Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
126.92
-1.60 (-1.24%)
At close: Apr 28, 2026, 4:00 PM EDT
127.85
+0.93 (0.73%)
After-hours: Apr 28, 2026, 7:59 PM EDT

Company Description

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.

The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

The company markets and distributes its products directly to customers, as well as through life-science distributors.

The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem.

It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease.

Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Illumina, Inc.
Illumina logo
Country United States
Founded 1998
IPO Date Jul 28, 2000
Industry Diagnostics & Research
Sector Healthcare
Employees 10,080
CEO Jacob Thaysen

Contact Details

Address:
5200 Illumina Way
San Diego, California 92122
United States
Phone 858 202 4500
Website illumina.com

Stock Details

Ticker Symbol ILMN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001110803
CUSIP Number 452327109
ISIN Number US4523271090
Employer ID 33-0804655
SIC Code 3826

Key Executives

Name Position
Jacob Thaysen Ph.D. Chief Executive Officer, Interim Chief Commercial Officer and Director
Ankur Dhingra CPA Chief Financial Officer
Kevin Carl Pegels Chief of Global Operations
Dr. Steven Barnard Ph.D. Chief Technology Officer
Stephanie Campos President
Scott Ericksen Vice President and Chief Accounting Officer
Mark Field Chief Information Officer
Conor Noel McNamara C.F.A. Vice President of Investor Relations
Scott Davies Chief Legal Officer and Secretary
Jakob Wedel Chief Strategy and Corporate Development Officer

Latest SEC Filings

Date Type Title
Apr 9, 2026 ARS Filing
Apr 9, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 9, 2026 DEF 14A Other definitive proxy statements
Apr 2, 2026 8-K Current Report
Mar 27, 2026 SCHEDULE 13G/A Filing
Feb 20, 2026 144 Filing
Feb 18, 2026 144 Filing
Feb 12, 2026 10-K Annual Report
Feb 5, 2026 8-K Current Report
Jan 30, 2026 8-K Current Report